|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.
Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. Juno Therapeutics is a pioneer in the booming cell therapy industry, where biotech companies are developing modified human immune cells to combat cancer cells.
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Gilead Sciences, Inc. (NASDAQ: GILD ) stands to benefit on multiple fronts, which prompted an analyst to upgrade the shares of the company Thursday. The Analyst Maxim Group analyst Jason McCarthy upgraded ...
Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?
Juno Therapeutics Inc. has announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry. Juno said the latest data from its lead product candidate, called JCAR017, are stronger than from Novartis Pharmaceuticals Corp. and Kite Pharma Inc. Both rivals recently won Food and Drug Administration approval to start selling their CAR-T (chimeric antigen receptor T cell) treatments. "There's been this odd belief that all CAR-Ts are the same," Juno President of Research and Development Dr. Sunil Agarwal said Wednesday.
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
Juno Therapeutics stock has been on the move as investors speculate on the next CAR-T buyout target. But there are other compelling reasons to own this stock right now.
Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!
Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire Kite Pharma, Inc.